Entera Bio/$ENTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Entera Bio
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Ticker
$ENTX
Sector
Primary listing
Employees
21
Headquarters
Jerusalem, Israel
Website
Entera Bio Metrics
BasicAdvanced
$63M
-
-$0.25
1.54
-
Price and volume
Market cap
$63M
Beta
1.54
52-week high
$3.22
52-week low
$0.91
Average daily volume
172K
Financial strength
Current ratio
6.944
Quick ratio
3.326
Long term debt to equity
1.985
Total debt to equity
3.74
Profitability
EBITDA (TTM)
-11.499
Net profit margin (TTM)
-27,235.71%
Operating margin (TTM)
-27,450.00%
Management effectiveness
Return on assets (TTM)
-56.78%
Return on equity (TTM)
-108.01%
Valuation
Price to revenue (TTM)
1,265.127
Price to book
4.05
Price to tangible book (TTM)
4.05
Price to free cash flow (TTM)
-7.104
Free cash flow yield (TTM)
-14.08%
Free cash flow per share (TTM)
-0.162
Growth
Revenue change (TTM)
-76.80%
Earnings per share change (TTM)
-2.28%
3-year revenue growth (CAGR)
-32.07%
3-year earnings per share growth (CAGR)
-18.28%
10-year earnings per share growth (CAGR)
-15.85%
Entera Bio News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Entera Bio stock?
Entera Bio (ENTX) has a market cap of $63M as of April 12, 2026.
What is the P/E ratio for Entera Bio stock?
The price to earnings (P/E) ratio for Entera Bio (ENTX) stock is 0 as of April 12, 2026.
Does Entera Bio stock pay dividends?
No, Entera Bio (ENTX) stock does not pay dividends to its shareholders as of April 12, 2026.
When is the next Entera Bio dividend payment date?
Entera Bio (ENTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Entera Bio?
Entera Bio (ENTX) has a beta rating of 1.54. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.